New Threads Only:  Add to Google Reader or Homepage
New Threads & Replies:  Add to Google Reader or Homepage
Forums are for serious investors only. GuruFocus Forum Rules.

Forum List » Guru News and Commentaries
Guru News, Stock picks and commentaries
New Topic Search
Goto Thread: PreviousNext
Goto: Forum ListMessage ListNew TopicSearchLog In
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse Inc, and NewLink Genetics Corp.
Posted by: GuruFocus (IP Logged)
Date: June 30, 2012 08:16AM

According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse Inc, and NewLink Genetics Corp. Universal Insurance Holdings, Inc. (UVE): CEO, 10% Owner Bradley I Meier sold 1,500,000 Shares

CEO, 10% Owner of Universal Insurance Holdings, Inc. (UVE) Bradley I Meier sold 1,500,000 shares on 06/22/2012 at an average price of $3.15. Universal Insurance Holdings, Inc., through its wholly-owned subsidiary, Universal Property & Casualty Insurance Company (UPCIC), is currently engaged in insurance underwriting, distribution and claims. Universal Insurance Holdings, Inc. has a market cap of $133.6 million; its shares were traded at around $3.4 with a P/E ratio of 5.3 and P/S ratio of 0.6. The dividend yield of Universal Insurance Holdings, Inc. stocks is 12.1%. Universal Insurance Holdings, Inc. had an annual average earnings growth of 0.3% over the past 5 years.

Universal Insurance Holdings reported net income of $9.9 million of $0.24 per diluted share and premium earned and other revenue of $60.2 million for the first financial quarter of 2012.

CEO, 10% Owner Bradley I Meier sold 1,550,000 shares of UVE stock in June.

Avanir Pharmaceuticals, Inc. (AVNR): President and CEO Keith Katkin sold 190,125 Shares

President and CEO of Avanir Pharmaceuticals, Inc. (AVNR) Keith Katkin sold 190,125 shares on 06/25/2012 at an average price of $3.5. AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir Pharmaceuticals, Inc. has a market cap of $470.9 million; its shares were traded at around $3.9 with and P/S ratio of 44.9.

Avanir Pharmaceuticals Inc. reported their 2012 second quarter fiscal results. The Company reported net revenue of $10.0 million and net loss of $17.0 million.

President and CEO Keith Katkin bought 10,000 and sold 190,125 shares of AVNR stock in March and June.SVP, R&D Joao Md Siffert bought 2,700 shares of AVNR stock on 05/10/2012 at the average price of 2.96. Vice President, Finance Christine Ocampo bought 3,000 shares of AVNR stock on 03/06/2012 at the average price of 2.6. Director Charles Mathews bought 5,000 shares of AVNR stock on 03/06/2012 at the average price of 2.69.

Bel Fuse, Inc. (BELFB): President and CEO Daniel Bernstein sold 171,185 Shares

President and CEO of Bel Fuse, Inc. (BELFB) Daniel Bernstein sold 171,185 shares on 06/22/2012 at an average price of $16.81. Bel Fuse Inc. is engaged in the design, manufacture and sale of products used in networking, telecommunication, automotive and consumer electronic applications. Bel Fuse, Inc. has a market cap of $36.6 million; its shares were traded at around $17.48 with a P/E ratio of 42 and P/S ratio of 0.1. The dividend yield of Bel Fuse, Inc. stocks is 1.7%. Bel Fuse, Inc. had an annual average earnings growth of 30% over the past 5 years.

Bel Fuse Inc. reported net income of $876 thousand and revenue of $65.6 million for the Company’s 2012 first quarter.

President and CEO Daniel Bernstein sold 171,185 shares of BELFB stock on 06/22/2012 at the average price of 16.81. Director Howard Bernstein sold 1,000 shares of BELFB stock on 06/05/2012 at the average price of 15.62.

NewLink Genetics Corp (NLNK): Chairman of the Board and CEO, 10% Owner Charles J. Jr. Link sold 150,000 Shares

Chairman of the Board and CEO, 10% Owner of NewLink Genetics Corp (NLNK) Charles J. Jr. Link sold 150,000 shares on 06/21/2012 at an average price of $15.66. NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Newlink Genetics Corp has a market cap of $347 million; its shares were traded at around $16.57 with and P/S ratio of 185.3.

NewLink Genetics Corp. reported net loss of $4.8 million and grant revenue of $471,000 for thier first quarter of 2012.

Chairman of the Board and CEO, 10% Owner Charles J. Jr. Link sold 150,000 shares of NLNK stock on 06/21/2012 at the average price of 15.66. CFO Gordon H Jr Link sold 5,187 shares of NLNK stock on 06/15/2012 at the average price of 15.49.

For the complete list of stocks that bought by their CEOs, go to: Insider Buys.



Stocks Discussed: UVE, AVNR, BELFB, NLNK,
Rate this post:

Rating: 3.5/5 (2 votes)





Sorry, only registered users may post in this forum.

Please Login if you have an account or Create a Free Account if you don't
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK